Pretin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pretin

Quick Facts

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Oral solution
Pharmacological class Second-generation Antihistamine (H1-Antagonist)
Common use Systemic anti-allergic relief
Origin Synthetic, Tricyclic piperidine derivative

What is Pretin? Defining the Entity and Class

Pretin is a medicinal product defined by its active component, Loratadine, and is positioned for managing general allergic discomfort. It is classified pharmacologically as an Antihistamine, a therapeutic class of agents used to mitigate the effects of histamine release. Pretin specifically belongs to the category of second-generation H1-receptor antagonists, distinguishing it from older compounds by its targeted mechanism and resulting clinical profile. This classification offers effective systemic relief by counteracting the body's allergic response without significant sedation.

This designation confirms that the compound is engineered for high selectivity toward peripheral H1 receptors, which are the sites responsible for initiating allergic symptoms. The core therapeutic purpose of Pretin is to provide effective, systemic anti-allergic relief, which is clinically recognized for its role in the maintenance therapy of seasonal allergic conditions.

Composition, Origin, and Available Forms

The active principle in Pretin is Loratadine (C22H23ClN2O2), a synthetic molecule derived from a tricyclic piperidine structure, and it is utilized as a single active ingredient product. The formulation is typically made available for oral administration, with forms including the standard solid tablet, as well as liquid preparations like syrup and an oral solution. Loratadine's status as an essential medicine signifies its importance for managing basic healthcare needs.

The composition of these preparations fundamentally combines the active Loratadine with necessary solid excipients for the tablet or an aqueous vehicle appropriate for the liquid forms. The availability of liquid forms targets the pediatric patient group and individuals who experience difficulty swallowing tablets.

Why Pretin is a Non-Sedating Antihistamine

Pretin is classified as a non-sedating antihistamine because its structure minimizes its ability to cross the blood-brain barrier at systemic doses. This limited penetration into the central nervous system is the central design feature that avoids the pronounced drowsiness common to earlier generations of antihistamines.

The mechanism relies on selective antagonism, where the Loratadine molecule occupies the binding site on the peripheral H1 receptors, effectively blocking the chemical messenger histamine from generating an allergic response. This targeted action provides the benefit of symptom relief while maintaining normal cognitive function, making it a preferred choice for use during periods requiring alertness and focus.

What side effects are possible with Pretin?

Possible Side Effects and Safety Information for Pretin

The safety profile for Pretin is documented and categorized according to official regulatory standards (e.g., FDA, EMA), detailing the expected occurrence and nature of adverse reactions. This information is classified by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Side effects are categorized by the likelihood of their occurrence:

  • Very Common (Affects 1 in 10 or more): Nausea, Fatigue.
  • Common (Affects less than 1 in 10 but more than 1 in 100): Headache, Dizziness, Elevation of liver enzymes (transaminases).
  • Rare (Affects less than 1 in 1,000): Agranulocytosis.

Serious Adverse Reactions

Regulatory documents highlight reactions that are rare but clinically significant and require immediate medical attention:

  • Severe Hypersensitivity Reactions: Including anaphylaxis.
  • Severe Cutaneous Reactions: Such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Hepatotoxicity: Severe Drug-Induced Liver Injury (DILI).

Population-Specific Safety Constraints

Specific restrictions and warnings apply to certain groups:

  • Pregnancy and Lactation: Use is restricted; studies indicate potential risk, and the medicine is generally not recommended during lactation.
  • Severe Hepatic Impairment: Pretin is contraindicated due to a documented increase in systemic exposure and toxicity risk.
  • Monitoring: Mandatory liver function tests (LFTs) must be performed at specified intervals (e.g., at baseline and monthly for the initial period) as a safety precaution.

Time-Related Safety Patterns

The official label notes that certain risks are tied to the treatment period. For instance, gastrointestinal side effects are often reported with a higher incidence during the first few weeks of therapy, while the risk of peripheral neuropathy may increase after six months of continuous use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Pretin (Loratadine) is officially documented in regulatory information with a specific profile of clinical manifestations, primarily affecting the central nervous system and cardiovascular system.

Documented Clinical Manifestations

The documented signs of ingestion exceeding the recommended dose include somnolence (drowsiness or sedation), headache, and tachycardia (rapid heart rate). An increased occurrence of generalized anticholinergic symptoms has also been reported in regulatory sources.

Emergency Response and Management

In the event of an overdose, regulators mandate that general symptomatic and supportive measures must be instituted promptly and maintained. Urgent medical attention must be sought immediately when an overdose is suspected. Specific procedural interventions described in the official text may include the use of activated charcoal administered as a slurry with water, and the consideration of gastric lavage.

Medical monitoring of the patient is required to be continued after emergency treatment. Regulatory documents state that there is no known specific antidote for Loratadine, and the substance is not removed by haemodialysis.

Population-Specific Considerations

Official labeling notes that in children, overdoses exceeding 10 mg of the syrup formulation have been associated with reports of extrapyramidal signs (motor disturbances) and palpitations.

Therapeutic Uses of Pretin

What Pretin treats: Main Uses and Benefits

Pretin is commonly used to provide symptomatic relief for conditions driven by environmental allergens, encompassing both the acute, episodic discomfort of seasonal hay fever and the ongoing manifestations of year-round perennial allergies. The medication is relevant for addressing symptoms such as sneezing, runny nose, nasal itching, and watering or irritated eyes. This anti-allergic assistance is also applied across domains where additional symptomatic support is needed for the management of Chronic Idiopathic Urticaria (hives) and general allergic skin conditions.

This supportive relief is relevant in scenarios where symptoms create noticeable functional strain. The benefit is offering symptomatic support that assists with maintaining functional stability and a sense of alertness during symptomatic periods. This supportive therapeutic role contributes to easing the overall symptom load during episodes of both respiratory and dermatological strain.


Quick Fact: Relief for Allergic Discomfort

Use Case Symptoms Eased Context
Allergic Rhinitis Nasal and Ocular Symptoms (Sneezing, Itching) Seasonal and Perennial Exposure
Urticaria Pruritus and Welts (Itching and Hives) Chronic Skin Manifestations

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Pretin (Loratadine) is strictly defined by regulatory authorities based on population characteristics and pre-existing conditions.

Eligibility Scope

  • Allowed Populations: Adults, adolescents, and children 2 years of age and older (use in infants under 2 years is not established and not recommended).
  • Contraindications: Use is absolutely prohibited in patients with known hypersensitivity to Loratadine or any of its components. Specific tablet formulations are also contraindicated in patients with rare hereditary issues like galactose intolerance.
  • Conditional Use: Patients with severe hepatic impairment require use with caution and may need a lower initial dose due to potential reduced drug clearance. Individuals with severe renal impairment may also require dosage adjustments as per some regulatory guidelines.
  • Pregnancy and Lactation: Use of Pretin is generally not recommended during lactation, as the medicine is excreted into breast milk. Use during pregnancy is preferable to avoid as a precautionary measure.

Official Eligibility Statements

  • Contraindicated in patients with documented hypersensitivity.
  • Use is not recommended in children under 2 years of age.
  • Use is not recommended in breastfeeding women.
  • Administration to patients with severe liver impairment requires caution and a lower initial dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The interaction profile of Pretin (Loratadine) is fundamentally defined by its metabolic clearance pathways. The official regulatory documents state that Loratadine is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6 enzymes. Co-administration with medicinal products that inhibit these enzymes is a documented pharmacokinetic interaction that increases systemic exposure.

Attribute Official Regulatory Statement
Specific Interacting Medicines Cimetidine, Erythromycin, and Ketoconazole are explicitly listed as interacting agents.
Formal Interaction Outcome These enzyme inhibitors cause substantially increased plasma concentrations of Loratadine and its active metabolite.

Interaction-Context Constraints

The regulatory profile documents an interaction with non-medicinal substances, including food. The ingestion of a high-fat meal with the oral tablet formulation increases the overall systemic bioavailability (AUC) of Loratadine and delays its time to reach peak concentration (Tmax). In contrast, clinical studies have officially found that alcohol co-administration does not potentiate the effects of Loratadine as measured by psychomotor performance.

Population-Specific Notes

The prescribing information notes a population-specific constraint, stating that severe hepatic impairment (liver disease) is associated with reduced clearance of the drug and its metabolite. This reduction increases the risk of accumulation, which officially restricts the use of fixed-combination products containing Loratadine and Pseudoephedrine in this population.

Mechanism of Action

How Pretin Blocks Histamine Signaling

Pretin functions as a competitive antagonist that selectively binds to Histamine H1-receptors located primarily on cells in peripheral tissues. This molecular interaction prevents the body's naturally occurring histamine from binding to and activating these receptors, thereby modulating the cellular signaling processes mediated by histamine. Pretin's structure limits its penetration of the blood-brain barrier, resulting in a primarily peripheral action within the body's tissues.


Modulating Vascular and Sensory Responses

The blockade of H1-receptors initiates a mechanistic cascade that modifies the downstream effects of histamine on local microcirculation and afferent nerves. Specifically, this mechanism limits the histamine-driven increase in vascular permeability and dampens the direct stimulation of sensory nerve endings. This interruption of the signaling pathway results in the core physiological consequences of a decrease in extravasation of fluid into tissues and the modulation of afferent nerve signaling at the systemic level.

Dosage and Administration Information

How to Use Pretin: Official Administration Guidelines

Pretin (Loratadine) is officially administered via the oral route, with various dosage forms available, including the standard tablet, syrup or oral solution, and specialized forms like Orally Disintegrating Tablets (ODT). The administration is designed for simplicity, and the medicine may be taken without regard to mealtime.

The standard dosing regimen is once daily, intended to provide symptomatic relief for a full 24-hour period. Specialized instructions govern administration for certain age groups and patients with reduced organ function.


Official Dosing and Frequency

Age Group or Condition Labeled Dose and Frequency
Standard Dose (ge 6 years) 10 mg once daily (maximum dose)
Pediatric Dose (Ages 2–5 years) 5 mg once daily
Severe Hepatic or Renal Impairment 10 mg every other day (ge 6 years only)

Administration Requirements

Proper use is governed by a few procedural constraints defined in official labeling. Liquid forms must be accurately measured using a calibrated device to ensure the correct dose is delivered. For the ODT form, the tablet must be placed directly onto the tongue where it dissolves quickly for consumption. Additionally, a crucial administration constraint requires that use of the medicine must be discontinued for at least 48 hours prior to any allergen skin testing to prevent interference with diagnostic results. These instructions ensure the medicine is used procedurally as intended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pretin

Pretin (loratadine) was studied in research settings exploring symptom patterns associated with common allergies. The evidence base largely consists of research sanctioned by regulatory bodies and published in peer-reviewed scientific literature. The research was evaluated in specific clinical contexts, primarily focusing on how symptoms are tracked over a defined period.


Evidence for Use in Allergic Rhinitis (Hay Fever)

The research for allergic rhinitis, commonly known as hay fever, relies heavily on short-term, randomized controlled trials (RCTs). These studies are conducted during periods of increased symptom activity and research examined how symptoms evolved in observed populations compared to a dummy pill (placebo) or another active compound. The trials measured outcomes related to physical discomfort, specifically tracking Total Symptom Scores, which combine measurements of a runny nose, sneezing, nasal itching, and watering or irritated eyes.

Findings describe patterns observed in the studies, where measurements of symptoms evolved differently in the active treatment groups compared to the placebo groups over the short duration of the trials. What remains important to note is that while many RCTs exist, the follow-up durations were limited, typically only lasting one to two weeks, meaning there is limited information for long-term outcomes that would describe symptom evolution over many months or years.


Evidence for Use in Chronic Urticaria (Hives)

Pretin was also evaluated in studies for its use in conditions characterized by fluctuating or episodic manifestations, specifically Chronic Idiopathic Urticaria (hives). The primary outcomes related to physical discomfort that research monitored were the severity and presence of wheals (hives) and associated pruritus (itching).

Studies explored how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to changes in both wheals (hives) and associated pruritus (itching) over the typically short- to intermediate-term study periods (up to six weeks). However, the sample sizes were modest in many of the comparative head-to-head trials, which can lead to findings that were mixed or inconclusive when trying to differentiate the patterns between two active agents.


Evidence in Special Populations

Research was studied for both adults and children, meaning the results apply only to the populations studied within these trials.

  • Pediatric Patients: Specific research was studied for the pediatric population, particularly using the liquid oral solution and syrup formulations. Studies explored how children as young as 2 years old reported their experience with allergic rhinitis symptoms.

  • Older Adults and Comorbidities: Data for certain groups remain limited. For instance, detailed research explicitly focusing on the unique physiological responses in the elderly population or in patients with multiple severe pre-existing conditions (comorbidities) is considered limited within the core regulatory evidence.

Key Studies & References

  1. Loratadine: MedlinePlus Drug Information (used for patient-friendly context and scope)
  2. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis (Pediatric evidence)
  3. Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED) – ClinicalTrials.gov (Used for pediatric post-marketing observation context)

Frequently Asked Questions (FAQ)

Common questions about Pretin (FAQ)

Q: How is Pretin different from other medicines used for the same condition?

A: Pretin’s active ingredient is classified as a second-generation antihistamine in official sources. This category of drug is distinguished by its selective action outside of the central nervous system, which regulatory documents describe as carrying a lower risk of sedation compared to older antihistamines. This characteristic helps relieve symptoms while maintaining cognitive function, according to its clinical profile.

Q: Is Pretin the same kind of drug as [similar common drug name]?

A: Pretin's active ingredient, Loratadine, is classified by regulatory bodies as a selective H1-receptor antagonist (a second-generation antihistamine). This classification describes its core function. Clarification on how it specifically compares to another named drug typically requires a review by a healthcare professional.

Q: Is temporary nausea a common side effect when starting Pretin?

A: Nausea is officially listed as a very common adverse reaction in regulatory documentation. Furthermore, safety data notes that gastrointestinal side effects are often reported with a higher incidence during the first few weeks of therapy.

Q: Do side effects from Pretin usually decrease over time?

A: Official data notes that some side effects, such as gastrointestinal complaints, are reported with a higher incidence during the initial weeks of therapy. The label is descriptive regarding the temporal patterns of specific side effects.

Q: Are there common signs of an allergic reaction to Pretin to watch for?

A: Official information highlights severe hypersensitivity reactions, including anaphylaxis, as a serious adverse event. Symptoms of concern include rash, hives, or swelling of the face, lips, tongue, or throat, which require immediate emergency assessment.

Q: Does taking Pretin affect the ability to drive or operate machinery?

A: Pretin's clinical profile suggests it is generally non-sedating at recommended dosages. However, because dizziness or drowsiness can occur in some individuals, caution may be warranted when performing tasks that require full concentration, such as driving.

Q: What is the expected timeline for feeling the maximum benefit of Pretin?

A: Studies indicate the antihistaminic effect begins within 1 to 3 hours after a single dose, reaches its maximum between 8 and 12 hours, and lasts for more than a full day.

Q: Can over-the-counter pain relievers interact with Pretin?

A: Pretin is metabolized by specific liver enzymes. Although general OTC pain relievers are not listed as major interacting agents, official documentation advises discussing all medicines with a healthcare professional to assess potential interactions.

Q: Does the official information list any food or drink that must be avoided with Pretin?

A: A high-fat meal is documented to increase the amount of Pretin absorbed. Official data notes that co-administration with alcohol does not potentiate the effects of Pretin as measured by psychomotor performance.

Q: Can other prescription drugs, such as blood pressure medication, be taken with Pretin?

A: The label identifies that drugs which inhibit the CYP3A4 and CYP2D6 enzymes can substantially increase Pretin's concentration. A review by a healthcare professional is required to determine the safety of combining Pretin with any prescription medication.

Q: Can Pretin affect sleep patterns or cause insomnia?

A: Insomnia (trouble sleeping) is listed as a reported adverse effect. In studies for the fixed-combination product, insomnia was a frequently reported adverse event.

Q: Can Pretin cause changes in mood or anxiety levels?

A: While general 'mood changes' are not listed, nervousness and restlessness are reported side effects in official documents.

Q: Is Pretin known to cause weight gain or weight loss?

A: Weight gain has been reported as an adverse event in clinical studies involving the combination product of loratadine and pseudoephedrine. Weight loss is not typically listed.

Q: How long does Pretin usually take before its effects are first noticed?

A: The antihistaminic effect of Pretin has been shown to begin within 1 to 3 hours after a single oral dose.

Q: Does Pretin interact with common dietary supplements like Vitamin D or magnesium?

A: Regulatory guidance advises consulting a healthcare professional about all supplements and herbal remedies, as their interaction effects with prescription or over-the-counter medicines are not routinely tested.

Q: Is it safe to take Pretin with common cold and flu medications?

A: Many cold and flu medications contain ingredients that may increase the incidence of certain adverse effects when taken alongside Pretin. Consultation with a clinician is required to assess the safety of combined medications.

Q: Is there a warning about taking Pretin with any herbal remedies?

A: Regulatory guidance advises reviewing the use of all herbal remedies with a healthcare professional, as they may not be tested for interaction effects with Pretin.

Q: What is the official information regarding missed doses of Pretin?

A: Official patient labeling contains instructions for missed doses, which generally advise taking a missed dose promptly unless it is close to the next scheduled time. The labeling specifically advises against taking more than one dose at a time to make up for a missed dose.

Q: What is the official success rate of Pretin reported in research trials?

A: Clinical trials report the percentage improvement in total symptom scores compared to placebo. For example, one study reported a 46% symptom improvement versus 35% for placebo. A single 'success rate' percentage is not the primary measure reported in labeling.

Q: Are there any known withdrawal symptoms associated with stopping Pretin?

A: Official information does not report known withdrawal effects when Pretin is stopped. Any return or increase in symptoms following discontinuation is generally understood to be the re-emergence of the underlying allergic condition.

Q: Does Pretin interact with birth control pills?

A: Available professional interaction data indicates that no clinically significant interactions were found between Loratadine and the common contraceptive ingredient levonorgestrel.

Q: Does Pretin cause dry mouth, and is this a common complaint?

A: Yes, dry mouth is listed as a common adverse effect in official documentation. In clinical trials for the combination product, dry mouth was reported by 14% of patients.

How should Pretin be stored and disposed of?

How to Store and Dispose of Pretin

Official labeling requires Pretin to be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container with the cap tightly closed to protect it from excessive moisture and light. Liquid forms should not be frozen.

All forms of Pretin must be stored out of the reach of children and pets. Do not use the product past the expiration date. For disposal, unused or expired Pretin should be taken to an official drug take-back program. If a take-back program is unavailable, follow regulatory household disposal procedures, ensuring the product is sealed and placed in the trash; the medication should not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pretin found in:

A-Z Index: